RKIP is a potentially valuable therapeutic target for SIRS since by inhibiting RKIP, IFNγ synthesis is stopped without shutting down responses to pathogen-associated molecular patterns (PAMPs). This evidence concerns the gene PEBP1 and systemic inflammatory response syndrome.